EXIRIS

Exiris is a preclinical stage company that uses a unique combination of technology platforms to discover novel oncology targets and to generate innovative therapeutic agents for the treatment of oncology indications with high unmet medical need... Exiris was founded in 2010 by a group of former Merck & Co. scientists to provide an answer to the challenges of oncology drug development. Despite the considerable progress in our understanding of human tumors and their underlying molecular biology, cancer is still one of the major causes of mortality in the western world. The difficulty of developing oncology drugs is highlighted by the low success rate of novel approvals: only 5% of new oncology drug candidates proceed from Phase 1 to regulatory approval... Exiris seeks to develop its products up to preclinical proof of concept and will partner clinical development. Exiris also provides its expertise and experimental platform on a fee-for-service basis. We are also open to co-development..

Also known as: Exiris srl

VAT numbers: 10897561006

Primary location: Rome Italy